AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02548780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
Study NCT03689972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg IV infusion.
Study NCT04014816 — intervention group
Intervention type: OTHER
Intervention: MDR bacteria positivity
Description: A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
Study NCT04014816 — intervention group
Intervention type: OTHER
Intervention: negative fluid balance
Description: A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
Study NCT00433121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Study NCT00433121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Study NCT00433121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidole
Study NCT00433121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapin
Study NCT00433121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Study NCT00433121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Study NCT00433121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertralin
Study NCT03902288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh pomegranate juice
Description: Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG \< 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
Study NCT03902288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh pomegranate juice
Description: Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG \< 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
Study NCT06116760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal or sham tDCS
Description: Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training.
Study NCT06116760 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal or sham tDCS
Description: Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training.
Study NCT06116760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual training
Description: 90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse.
Study NCT03689972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg SC injection or IV infusion.
Study NCT02068950 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Progressive resistance training
Description: A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
Study NCT04128605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB)
Description: SSNB is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. Then, a mixture of 5 mls of Bupivacaine, 5 mls Lidocaine 1% and 10 mls of saline are injected at posterior shoulder towards suprascapular notch surrounding suprascapular nerve.
Study NCT04128605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular shoulder steroid injection (IAS)
Description: IAS is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. IAS is performed by injecting 40 mg of Triamcenolone Acetonide along with 2 ml of Lidocaine 1% into glenohumeral articular space
Study NCT01318525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALF-5755
Description: 10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
Study NCT01318525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution (0.9% NaCl)
Description: 25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
Study NCT01391455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolation of the spermatic cord from mesh
Description: The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
Study NCT04446299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowel Prep
Description: Orally ingested liquid bowel preparation
Study NCT04446299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Prep
Description: Orally ingested liquid bowel preparation
Study NCT03322397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Focused Acts of Kindness Intervention
Description: Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
Study NCT03322397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other-Focused Acts of Kindness Intervention
Description: Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
Study NCT03322397 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Daily Reports
Description: Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
Study NCT02813863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086
Study NCT02813863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03087708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: Given PO
Study NCT03087708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03087708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03087708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03087708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03087708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03087708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00929136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: USP endotoxin
Description: Continuous intra-arterial infusion
Study NCT00618813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00618813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00618813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00618813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00618813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00618813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00618813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00618813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00618813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT01150604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help cognitive-behavioral online course
Description: A self-help online course based on cognitive behavioral therapy for major depression.
Study NCT04054739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training
Description: intervention with robot-assisted gait training
Study NCT04054739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill gait training
Description: intervention with treadmill gait training
Study NCT03221660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F-Composite 2 system
Description: Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
Study NCT00453661 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only.
Study NCT00453661 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Navigator (PN)
Description: Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
Study NCT01194414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab SC
Description: Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
Study NCT01194414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab IV
Description: Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
Study NCT01194414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to tocilizumab SC
Description: Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
Study NCT01194414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to tocilizumab IV
Description: Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
Study NCT01194414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Description: stable dose as prescribed
Study NCT02525952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Surgical removal of all lesions
Study NCT02525952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transarterial chemoembolization with lipiodol and pirarubicin
Study NCT03015623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBI-101
Description: SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
Study NCT03015623 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
Study NCT01080612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 330 mg pregabalin controlled release
Description: A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
Study NCT01080612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 330 mg pregabalin controlled release
Description: A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
Study NCT01080612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 330 mg pregabalin controlled release
Description: A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
Study NCT01080612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 300 mg pregabalin immediate release
Description: A single dose of 300 mg immediate release capsule will be administered in the fasted state
Study NCT00995605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMAP102
Description: AMAP102 or Placebo
Study NCT06116760 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Audio-visual training
Description: 90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse.
Study NCT01016197 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extensor tendon repair
Description: Surgical repair of extensor tendon with bone anchor and splinting
Study NCT01016197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mallet splint for 4 weeks
Description: The patient will wear a mallet splint for fours weeks and then mobilise their finger.
Study NCT02228200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Description: The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
Study NCT02228200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
Study NCT02228200 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
Study NCT01378637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES- Leg treatment
Description: 30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
Study NCT04145557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: diode laser 980nm
Description: Procedure: Periodontal therapy with laser Scaling, root planning, oral hygiene instruction and diode laser 980nm treatment of periodontal pockets
Study NCT04145557 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: scaling root planing
Description: scaling and root planing
Study NCT02124330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: montmorillonite 5 g
Description: 5g montmorillonite + 15 g protein (ratio 1:3)
Study NCT02124330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: montmorillonite 3 g
Description: 3g MONT+ 15 g protein (ratio 1:5)
Study NCT02124330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorillonite 1 g
Description: 1g MONT+ 15 g protein (ratio 1:15)
Study NCT00571948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: more meat and a vegetable oil rich in omega-3 fatty acids
Description: The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids).
Study NCT00571948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: more meat and a vegetable oil rich in omega-3 fatty acids
Description: The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids).
Study NCT00571948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Babyfood with usual meat content and corn oil
Description: The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
Study NCT00571948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Babyfood with usual meat content and corn oil
Description: The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
Study NCT04112784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00039
Description: Noninvasive pulse oximeter sensor
Study NCT01938456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
Study NCT04159922 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
Study NCT03432117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed respiratory rehabilitation
Description: There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
Study NCT01938456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
Study NCT01938456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter\^2 or 75 mcg/body
Study NCT04138121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the cricothyroid membrane